uniQure (QURE) Shares Plunge Over 50% Premarket After Mixed AMT-
uniQure NV (QURE) shares dropped over 50% premarket after mixed Phase 1/2 trial results for its AMT-130 gene therapy. The 36-month data showed an 80% reduction in Huntington’s disease progression, but the 48-month data showed only a 44% reduction, failing to reach statistical significance. The company has a P/S ratio of 131.68x, significantly higher than its historical median of 35.54x, and a GF Score of 48/100, reflecting weak profitability and financial strength but moderate growth potential.
How this was made
The 30-second read
Why it matters
The mixed efficacy data undermines investor confidence, driving a sharp sell‑off and raising questions about the therapy's commercial viability.
Market read
First disclosure of trial data; immediate price impact makes the article highly relevant for traders.
What to watch
potential BMS partnership could provide non‑clinical revenue support.
Background
uniQure (NASDAQ: QURE) announced mixed Phase 1/2 results for its Huntington's disease gene therapy AMT‑130, causing a >50% pre‑market plunge.
Ticker impact
Phase 1/2 AMT-130 trial showed mixed efficacy, triggering a >50% pre‑market drop.
likely further downside pressure as investors re‑evaluate the therapy's potential.
The data release is the first public disclosure of the trial outcomes; the market reacted strongly and the stock remains volatile.
Market effects
gene‑therapy biotech sector faces heightened risk perception.
US biotech equities may see broader pressure.
impact limited to biotech investors and related pharma partners.
Counterpoint
price may be oversold if later data shows improved durability.
Key entities
- companyuniQure NV
Dutch gene‑therapy biotech listed on NASDAQ.
- partnerBristol Myers Squibb
Collaborates with uniQure on cardiovascular gene therapies.
